The presence of tumor infiltrating lymphocytes (TILs) influences the clinical outcome of
cancer patients and immune checkpoint inhibitors (ICPI) have been approved for treating …

Simple Summary Recently, cancer treatment has been revolutionized by introduction of
immunotherapy—drugs that target body's immune system to attack cancer. Most clinically …

Immunotherapy, mainly in the form of immune checkpoint inhibitors (ICIs), has been
transformative in both solid tumor and hematologic malignancies. Patients with previously …

Advanced and recurrent gynecological cancers are associated with a poor prognosis and
there is still a lack of effective treatments. Immune checkpoint blockade (ICB) therapy is an …

Standard treatments for gynecological cancers include surgery, chemotherapy, and
radiation therapy. However, there are limitations associated with the chemotherapeutic …

Purpose The goal of this study was to compile a review of topics pertinent to the use of
immune checkpoint inhibitors in gynecologic malignancies, including foundation for use …

Simple Summary Most endometrial cancer patients are diagnosed at an early stage, receive
standard treatment, and survive well. Ovarian cancer has no specific symptoms and usually …

There is mounting evidence that the immune system plays an important role in the
development and growth of gynecologic malignancies, and preliminary studies show activity …

Background Immune checkpoints are regulatory molecules that suppress immune effector
cells, and are essential for maintaining tolerance, preventing autoimmune reactions, and …

Advanced gynecologic cancers have historically lacked effective treatment options.
Recently, immune checkpoint inhibitors (ICIs) have been approved by the US Food and …